1.     Kostova D, Reed C, Finelli L, Cheng P-Y,Gargiullo PM, Shay DK, et al. Influenza Illness and Hospitalizations Averted byInfluenza Vaccination in the United States, 2005-2011. PLOS ONE [Internet]2013;8(6):e66312.

2.     Casado I, Domínguez A, Toledo D, Chamorro J,Force L, Soldevila N, et al. Effect of influenza vaccination on the prognosisof hospitalized influenza patients. Expert Rev Vaccines. 2016;15(3):425-32.

3.      MosnierA, Daviaud I, Caini S, Berche H, Mansuy J-M, van der Werf S, et al. Doesseasonal vaccination affect the clinical presentation of influenza among theelderly? A cross-sectional analysis in the outpatient setting in France,2003–2014. Vaccine. 2017;35(16):2076-83.

4.     Beyer WEP, McElhaney J, Smith DJ, Monto AS,Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: Support for policies tovaccinate elderly people against influenza. Vaccine. 2013;31(50):6030-3.

5.     Domnich A, Arata L, Amicizia D, Puig-Barberà J,Gasparini R, Panatto D. Effectiveness of MF59- adjuvanted seasonal influenzavaccine in the elderly: A systematic review and meta-analysis. Vaccine.2017;35(4):513-20.

6.     Lee W-J, Chen L-K, Tang G-J, Lan T-Y. The impactof influenza vaccination on hospitalizations and mortality among frail olderpeople. J Am Med Dir Assoc. 2014;15(4):256-60.

7.     Cruzeta APS, Schneider IJC, Traebert J. Impactof seasonality and annual immunization of elderly people upon influenza-relatedhospitalization rates. Int J Infect Dis. 2013;17(12):e1194-e7.

8.     Torner N, Navas E, Soldevila N, Toledo D,Navarro G, Morillo A, et al. Costs associated with influenza-relatedhospitalization in the elderly. Hum Vaccin Immunother. 2017;13(2):412-6.

9.     Udell JA, Zawi R, Bhatt DL, et al. Associationbetween influenza vaccination and cardiovascular outcomes in high-riskpatients: A meta-analysis. JAMA. 2013;310(16):1711-20.

10.  HughesM, Reed C, Flannery B, Garg S, Singleton J, Fry A, Rolfes M. ProjectedPopulation Benefit of Increased Effectiveness and Coverage of InfluenzaVaccination on Influenza Burden – United States. Clin Infect Dis2020;70(12):2496-2502

11.  PellegriniM, Nicolay U, Lindert K, Growth N, Della Cioppa G. MF59-adjuvanted versusnon-adjuvanted influenza vaccines: Integrated analysis from a large safetydatabase. Vaccine. 2009;27(49):6959-65

12.  FreySE, Reyes MRA-DL, Reynales H, Berman NN, Nicolay U, Narasimhan V, et a.Comparison of the safety and immunogenicity of an MF59®-adjuvanted with anon-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine.2014;32(39):5027-34

13.  CowlingBJ, Thompson MG, NGTWY, Fang VJ, Perera RAPM, Leung NHL, et al. Comparativereactogenicity of enhanced influenza vaccines in older adults. J Infect Dis.2020;222(8):1383-91

14.  SchultzeV, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant.Vaccine. 2008; 26(26):3209-22

15.   Ferdinands JM, Blanton LH, Alyanak E, et al.Protection against influenza hospitalizations from enhanced influenza vaccinesamong older adults: A systematic review and network meta-analysis. J Am GeriatrSoc. 2024;72(12):3875-89.

16.  KuJH, Rayens E, Sy LS, et al. Comparative Effectiveness of Licensed InfluenzaVaccines in Preventing Influenza-related Medical Encounters andHospitalizations in the 2022-2023 Influenza Season Among Adults >/=65 Yearsof Age. Clin Infect Dis. 2024;79(5):1283-92.

17.  LapiF, Marconi E, Simonetti M, Baldo V, Rossi A, Sessa A,et al. Adjuvanted versusnonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia andcerebro/cardiovascular events in the elderly. Expert Rev Vaccines.2019;18(6):663- 70.

18.  Puig-BarberaJ, Diez-Domingo J, Varea AB, Chavarri GS, Rodrigo JAL, Hoyos SP, et al.Effectiveness of MF59™adjuvanted subunit influenza vaccine in preventinghospitalisations for cardiovascular disease, cerebrovascular disease andpneumonia in the elderly. Vaccine.2007;25(42):7313-21.

‍

‍